

Article

Tuning Mesenchymal Stem Cell Response onto Titanium-Niobium-Hafnium Alloy by Recombinant Fibronectin Fragments

Carolina Herranz-Diez, Carlos Mas-Moruno, Stefanie Neubauer, Horst Kessler, Francisco Javier Gil, Marta Pegueroles, José Maria Manero, and Jordi Guillem-Martí

ACS Appl. Mater. Interfaces, **Just Accepted Manuscript** • DOI: 10.1021/acsami.5b09576 • Publication Date (Web): 06 Jan 2016

Downloaded from <http://pubs.acs.org> on January 7, 2016

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.



1
2
3 **Tuning Mesenchymal Stem Cell Response onto Titanium-Niobium-Hafnium Alloy by**
4
5 **Recombinant Fibronectin Fragments**
6
7
8

9 C. Herranz-Diez^{a,1}, C. Mas-Moruno^{a,b}, S. Neubauer^{c,d}, H. Kessler^{c,d}, F.J. Gil^{a,b}, M.
10 Pegueroles^{a,b}, J.M. Manero^{a,b}, J. Guillem-Marti^{a,b*}
11
12

13
14
15 ^aBiomaterials, Biomechanics and Tissue Engineering Group, Department of Materials
16 Science and Metallurgical Engineering, Technical University of Catalonia (UPC), ETSEIB,
17 Diagonal 647, 08028 Barcelona, Spain.
18
19

20
21
22 ^bCentre for Research in NanoEngineering (CRnE)-UPC, c/Pascual i Vila 15, 08028
23 Barcelona, Spain
24
25

26
27
28 ^c Institute for Advanced Study and Center for Integrated Protein Science, Department
29 Chemie, Technische Universität München, Lichtenbergstr. 4, 85747 Garching, Germany.
30
31

32
33 ^d Max Planck Institute for Intelligent Systems, Heisenbergstr. 3, 70569 Stuttgart, Germany
34
35

36 *Corresponding author: Dr. J. Guillem-Marti: Biomaterials, Biomechanics and Tissue
37 Engineering Group, Department of Materials Science and Metallurgy, Technical University
38 of Catalonia (UPC), ETSEIB, Av. Diagonal 647, 08028 Barcelona, Spain.
39
40
41

42
43 E-mail address: jordi.guillem.marti@upc.edu
44
45

46 1. Present address: Academic Unit of Restorative Dentistry, School of Clinical Dentistry,
47 University of Sheffield, Claremont Crescent, Sheffield S10 2TA, UK.
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Since metallic biomaterials used for bone replacement possess low bioactivity, the use of cell adhesive moieties is a common strategy to improve cellular response onto these surfaces. In recent years the use of recombinant proteins has emerged as an alternative to native proteins and short peptides owing to the fact that they retain the biological potency of native proteins, while improving their stability. In the present study, we investigated the biological effect of two different recombinant fragments of fibronectin, spanning the 8th-10th and 12th-14th type III repeats, covalently attached to a new TiNbHf alloy using APTES silanization. The fragments were studied separately and mixed at different concentrations and compared to a linear RGD, a cyclic RGD and the full-length fibronectin protein. Cell culture studies using rat mesenchymal stem cells demonstrated that low to medium concentrations (30% and 50%) of type III 8th-10th fragment mixed with type III 12th-14th fragment stimulated cell adhesion and proliferation compared to RGD peptides and the fragments separately. On the other hand, type III 12th-14th fragment alone or mixed at low volume percentages $\leq 50\%$ with type III 8th-10th fragment increased alkaline phosphatase levels compared to the other molecules. These results are significant for the understanding of the role of fibronectin recombinant fragments in cell responses and thus to design bioactive coatings for biomedical applications.

KEYWORDS: Fibronectin; recombinant protein; cell adhesive peptides; mesenchymal stem cells; titanium alloy

1. INTRODUCTION

Titanium (Ti) and Ti-based alloys have been traditionally used for bone implantation purposes.¹ Despite the good biocompatible properties showed by these materials, there is a mismatch with bone elastic modulus, which is translated in a stress shielding effect.² In a bone replacement scenario, the prosthesis shares the load and carrying capacity of bone. The loads applied to bone are reduced leading to a new loads distribution and eventually to bone resorption, which is a major cause of implant failure. Ductile metals such as Zr, Ta, Nb or Hf are used to stabilize the beta phase in Ti-alloys,³⁻⁵ which is the phase with lowest elastic modulus, and also because they possess osseoinductive properties.⁶ A particularly interesting Ti-based alloy is the TiNbHf ternary system. This system has shown interesting properties such as low elastic modulus, good biocompatibility and no cytotoxic effects.^{7,8} In this regard, we have recently developed the Ti₂₅Nb₂₁Hf alloy, which exhibited lower elastic modulus and higher wear resistance compared to Ti.⁹

Despite the interesting biocompatibility and mechanical properties exhibited by TiNbHf alloys, these metallic biomaterials are not bioactive and thus do not promote osseointegration at an optimal rate, compromising in some circumstances the long-lasting stability of the implants. For this reason, in recent years several efforts have concentrated on the biofunctionalization of the biomaterials surface to improve their bioactivity and hence their osseointegration.¹⁰ In detail, the main goal of biofunctionalization is to generate an extracellular matrix (ECM)-like environment that positively influences the behaviour of osteoblast and bone precursors (i.e. mesenchymal stem cells, MSCs) and effectively guides bone growth.^{11,12} The ideal strategy is the use of native bone ECM proteins, such as collagen or fibronectin (FN), for coating the surfaces.^{13,14}

However, although these proteins retain their full biological functionality and specificity, they display low stability after functionalization along with many other drawbacks including

1
2
3 high production costs and immunogenicity, which have reduced their biomedical potential.¹¹

4
5 The use of ECM-derived synthetic peptides containing the functional sites of ECM proteins is
6
7 an interesting approach to overcome these problems.^{10,11} The advantages of these motives in
8
9 regards to ECM proteins are their higher stability, lower production costs and their capability
10
11 to be synthetically tailored in composition for specific biological applications.

12
13
14 In particular, integrin-binding sequences are of great interest since they regulate not only cell
15
16 adhesion but also cell survival, proliferation and differentiation. This is illustrated by the cell
17
18 adhesive arginine-glycine-aspartic acid (RGD) motif, which is present in many ECM proteins
19
20 including FN, vitronectin, bone sialoprotein and osteopontin, and has been widely used to
21
22 mimic cell/matrix interactions and improve the osteointegration of implant materials.^{10-12,15}

23
24
25 Nonetheless, short synthetic peptides are commonly less functional and specific than full-
26
27 length proteins due to the absence of complementary domains required for biological activity
28
29 or inadequate conformation, both of which are crucial to trigger an appropriate cell
30
31 response.¹⁶ To solve these problems, different approaches aiming at improving the activity
32
33 and selectivity profile of integrin ligands have been followed: cyclic peptides,¹⁷⁻¹⁹
34
35 peptidomimetics,²⁰⁻²³ mixtures of peptides²⁴⁻²⁶ or peptide-based platforms.²⁷

36
37
38 The use of recombinant protein fragments for functionalizing surfaces has emerged as a
39
40 potential strategy that combines the benefits of the aforementioned methods.²⁸⁻³¹ Using
41
42 recombinant DNA technology the signalling domain of an ECM protein can be engineered to
43
44 retain crucial biological features such as the conformation and spacing of bioactive
45
46 sequences, while reducing the antigenicity and improving the stability of native proteins.
47
48 Noteworthy, fusion of more than one domain from the same protein or domains from
49
50 different proteins can be assembled modulating different cell responses with only one
51
52 molecule.³²⁻³⁴

53
54
55
56
57
58
59
60

1
2
3 FN is a well-known ECM protein that mediates many cellular processes like cell adhesion,
4 migration, growth and differentiation.³⁵ FN contains a region involved in cell adhesion
5 located in the type III₁₀ domain, which includes the above-mentioned RGD sequence. In
6
7 addition, the type III₉ domain contains the PHSRN (Pro–His–Ser–Arg–Asp) sequence, which
8
9 strongly modulates and increases the binding affinity of RGD to $\alpha_5\beta_1$ integrin.^{35,36}
10
11

12
13
14 Previous studies have demonstrated that the cell attachment site (CAS) recombinant fragment
15 of FN, consisting of type III₈₋₁₀ repeats or III₇₋₁₀ enhances cell adhesion, proliferation and
16 differentiation.^{28,37} Studies by Martino et al.³¹ demonstrated the good adhesion and
17 osseointegration potential of MSCs in contact with the FNIII₉₋₁₀ fragment. Petrie et al.³⁰
18 showed the capacity of the FN III₇₋₁₀ fragment to increase osteoblastic differentiation and
19 mineralization *in vitro* and enhanced implant osseointegration in a rat cortical bone model
20 compared to RGD and fibronectin. In vivo studies by Agarwal et al. demonstrated that the FN
21 III₇₋₁₀ fragment promotes $\alpha_5\beta_1$ integrin-dependent adhesion and osteogenic differentiation of
22 hMSCs.³⁸
23
24

25
26
27 Besides the CAS, there is another region in FN, the C-terminal type III₁₂₋₁₄ heparin-binding II
28 (HBII) domain also crucially involved in cytoskeletal organization and focal adhesion
29 formation. This HBII domain binds to proteoglycans, including heparan sulfate proteoglycans
30 (HSPGs) such as syndecans.³⁹ For instance, syndecan-4 has been described to play an
31 important role in the regulation of the activation of several integrins through the HBII
32 domain.⁴⁰ Moreover, it has been shown that HB domains in FN enhance cell adhesion and
33 proliferation of osteoblasts together with the CAS domain.³⁹ Another important feature of the
34 HBII domain was described by Martino et al.⁴¹ In his studies, its capability to sequester
35 growth factors from different families was demonstrated.
36
37

38
39
40 The present work aims to covalently functionalize a Ti25Nb21Hf alloy with FNIII₈₋₁₀ and
41 FNIII₁₂₋₁₄ recombinant fragments alone or combined at different concentrations to elucidate
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 the importance of each fragment on the biological response for implant applications. These
4
5 sequences have been compared to FN and two short synthetic RGD peptides (linear and
6
7 cyclic, linRGD and cRGD, respectively). Cellular behaviour has been analysed in terms of
8
9 cell adhesion, proliferation and differentiation using rat mesenchymal stem cells (rMSCs).
10

11 12 13 **2. MATERIALS AND METHODS**

14 15 **2.1. TiNbHf alloy fabrication and preparation**

16
17 The alloy was fabricated as described in ⁹. Briefly, commercially pure (CP)-Ti, Nb (99.8%
18
19 purity) and Hf (99.7% purity) were arc melted and vacuum homogenized. Bars of diameter
20
21 10 mm were obtained by extrusion. TiNbHf alloy bars were cut in discs of 2 mm thickness
22
23 and grinded with SiC papers of grit 320, 800, 1200 and 2500 (Struers, Spain). After grinding,
24
25 the discs were mirror polished with colloidal silica (size particle 0.05 μm , ATM GmbH,
26
27 Germany). Samples were cleaned in an ultrasound bath with cyclohexane, isopropanol,
28
29 ethanol, deionized water and acetone (all chemicals were of the highest purity available from
30
31 Sigma-Aldrich, USA).
32
33

34 35 36 **2.2. Recombinant FN fragments**

37
38 Recombinant DNA techniques were used to synthesize two different fragments of human FN:
39
40 i) the Cell Attachment Site (CAS) sequence, spanning the 8th–10th type III repeats, and ii)
41
42 the Heparin Binding II (HBII) sequence spanning the 12th–14th type III repeats. DNA
43
44 extracted from SaOS-2 cells was specifically amplified by PCR using 5'-
45
46 GTCGACAAGTTCCTCCTCCCACTGACCT-3' and 5'-
47
48 GCGGCCGCTTAATGGAAATTGGCTTGCTG-3' (for CAS domain) or 5'-
49
50 GTCGACAAGCTATTCCTGCACCAACTGA-3' and 5'-
51
52 GCGGCCGCTGTCTTTTTCCTTCCAATCAGG-3' (for HBII domain). Each DNA fragment
53
54 was digested with SalI and NotI (New England Biolabs, USA) and ligated into a pGEX-6P-1
55
56
57
58
59
60

1
2
3 plasmid (GE Healthcare, UK). The resulting constructs, containing CAS or HBII with a
4 glutathione S-transferase (GST) tagging sequence at the amine terminus, were separately
5 amplified in DH5 α cells (Invitrogen, USA), purified and sequenced. Then, BL21 *E.coli*
6 strains (Invitrogen) were separately transformed with the plasmids and streaked onto LB agar
7 plates containing 100 μ g/ml of ampicillin and incubated at 37 $^{\circ}$ C overnight. Colonies were
8 isolated and dynamically cultured in LB broth (Sigma-Aldrich) with 100 μ g/ml of ampicillin
9 at 37 $^{\circ}$ C until they reached an OD₆₀₀=0.6. Expression of the fragments was induced by
10 addition of 1 mM IPTG. After 4 h, cells were harvested by centrifugation and lysed by
11 sonication. Then, 20% Triton X-100 was added and the suspension was incubated at 4 $^{\circ}$ C for
12 30 min under mild agitation. The suspension was then centrifuged and the supernatant was
13 purified at 4 $^{\circ}$ C using GSTrap affinity columns (GE Healthcare) in an ÄKTA purifier (GE
14 Healthcare). GST tag was on-column removed by cleavage with HRV3C Protease (Sigma-
15 Aldrich) in Cleavage Buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1 mM
16 dithiothreitol, pH 7.0). Purity was verified to be >95% by SDS-PAGE. Protein concentrations
17 were determined by BCA assay (Pierce, Thermo Fisher Scientific, USA).

2.3. Synthesis of linear RGD peptide (linRGD)

37
38 The linear peptide MPA-Ahx-Ahx-Ahx-Gly-Arg-Gly-Asp-Ser-OH (**linRGD**) (Ahx:
39 aminohexanoic acid; MPA: 3-mercaptopropionic acid) was manually synthesized by solid-
40 phase peptide synthesis (SPPS) following the Fmoc/tBu strategy⁴² and using 2-chlorotriyl
41 chloride resin (CTC, 200 mg, 1.6 mmol/g) (Iris Biotech GmbH, Germany) as solid support.
42 Fmoc-L-amino acids were obtained from Iris Biotech GmbH and coupling reagents from
43 Sigma-Aldrich and Luxembourg Industries Ltd. (Israel). All other chemicals and solvents
44 were acquired from Sigma-Aldrich, Alfa Aesar (Germany) and SDS (France). The first amino
45 acid was incorporated by sequential addition of Fmoc-Ser(tBu)-OH (1 equiv) and N,N-
46 diisopropylethylamine (DIEA) (10 equiv). After 1 h under stirring the resin was capped with
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 MeOH (0.8 mL/g of resin). The Fmoc group was removed by treatment with piperidine/*N,N*-
4 dimethylformamide (DMF) (1:4, v/v) and the following coupling reactions were carried out
5 with Fmoc-L-amino acids (4 equiv), Oxyma Pure (4 equiv) and *N,N'*-
6 diisopropylcarbodiimide (DIC) (4 equiv) in DMF for 45 min. The efficiency of each reaction
7 was monitored using the Kaiser test and by analytical HPLC analysis (Waters Alliance 2695
8 chromatography system) (Waters, USA). After synthesis, the peptide was cleaved from the
9 solid support with concomitant deprotection of the side chain protecting groups. To this end,
10 the resin was washed with dichloromethane (DCM), dried, and treated with trifluoroacetic
11 acid (TFA)/H₂O/triisopropylsilane (TIS) (95:2.5:2.5) for 1.5 h. The peptide was then
12 precipitated with cold diethyl ether, centrifuged and washed twice with diethyl ether. This
13 crude peptide was dissolved in H₂O/MeCN (1:1, v/v) and lyophilized. Purification of the
14 peptide was achieved by semi-preparative HPLC (Waters Delta 600 instrument) using linear
15 gradients from 0 to 10 % MeCN over 2 min and 10 to 30 % MeCN over 10 min. The purified
16 peptide was characterized by analytical HPLC (10 to 40 % MeCN over 8 min, $t_R = 4.227$
17 min) and MALDI-TOF (Applied Biosystems, USA) (m/z calcd. for C₃₈H₆₇N₁₁O₁₃S: 917.46,
18 found: 918.30 [M+H]⁺; 940.28 [M+Na]⁺; 956.25 [M+K]⁺).

2.4. Synthesis of cyclic RGD peptide (cRGD)

20
21 The cyclic peptide MPA-Ahx-Ahx-Ahx-cyclo(-RGDfK-) (**cRGD**) was synthesized as
22 previously described^{19,43,44}. In brief, the thiol-protected anchor MPA(Trt)-Ahx-Ahx-Ahx-OH
23 (1 equiv), 1-hydroxy-7-azabenzotriazole (HOAt) (1.2 equiv) and *N*-[(dimethylamino)-1*H*-
24 1,2,3-triazolo[4,5-*b*]pyridino-1-ylmethylene]-*N*-methylmethanaminium hexafluorophosphate
25 (HATU) (1.2 equiv) were dissolved in anhydrous DMF (0.022 M) and pre-activated for 3 h
26 at room temperature in the presence of DIEA (5 equiv). Next, cyclo(-R(Pbf)GD(OtBu)fK-) (1
27 equiv) dissolved in anhydrous DMF was added to the reaction mixture and allowed to react
28 under stirring overnight at room temperature. After reaction, DMF was evaporated to
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 dryness, a saturated solution of NaHCO_3 was added and the crude product was extracted with
4 EtOAc thrice. The organic layer was washed with brine, dried with Na_2SO_4 and evaporated.
5
6 The peptide was next treated with TFA/ H_2O /TIS (95:2.5:2.5) for 1.5 h. The peptide was
7
8 finally precipitated with cold anhydrous diethyl ether, washed twice with this solvent and
9
10 lyophilized. Semi-preparative HPLC purification (linear gradients from 0 to 10 % MeCN
11
12 over 2 min and 10 to 40 % MeCN over 15 min) yielded the peptide as a white powder. The
13
14 purified peptide was characterized by analytical HPLC (10 to 40 % MeCN over 8 min, $t_R =$
15
16 6.578 min) and MALDI-TOF (m/z calcd. for $\text{C}_{48}\text{H}_{78}\text{N}_{12}\text{O}_{11}\text{S}$: 1030.56, found: 1031.39
17
18 $[\text{M}+\text{H}]^+$; 1053.37 $[\text{M}+\text{Na}]^+$; 1069.35 $[\text{M}+\text{K}]^+$).

23 24 **2.5. Sample biofunctionalization**

25 26 **2.5.1. Silanization**

27
28 Samples were silanized in order to covalently attach the molecules to the substrate. TiNbHf
29
30 samples and Quartz Crystal Microbalance with Dissipation Monitoring (QCM-D) Ti sensors
31
32 (QSX310, Q-Sense, Sweden) were first cleaned in an ultrasound bath with cyclohexane,
33
34 isopropanol, ethanol, deionized water and acetone, and then cleaned and activated with
35
36 oxygen plasma for 5 min at a 12 MHz frequency in an Expanded Plasma Cleaner PDC-002
37
38 (Harrick Scientific Corporation, USA). Then, samples were immersed in a 0.08 M solution of
39
40 (3-aminopropyl)triethoxysilane (APTES, Sigma-Aldrich) in toluene (Sigma-Aldrich) at 70 °C
41
42 for 1 h under agitation in an inert atmosphere. After silanization, samples were ultrasonicated
43
44 in toluene for 5 min and cleaned with toluene (3x), acetone (1x), isopropanol (3x), distilled
45
46 water (3x), ethanol (3x) and acetone (3x). Subsequently aminosilanized samples were
47
48 immersed in a 7.5 mM solution of N-succinimidyl-3-maleimidepropionate (SMP) in DMF for
49
50 1 h under agitation at room temperature. The cross-linked samples were rinsed in DMF (3x),
51
52 acetone (1x), distilled water (10x), ethanol (3x) and acetone (3x) and dried with nitrogen.
53
54
55
56
57
58
59
60

2.5.2. Molecules immobilization

linRGD and cRGD were used at a concentration of 100 μM and CAS and HBII were used at a concentration of 100 $\mu\text{g/ml}$ (concentrations optimized in previous studies in our group). FN (Sigma-Aldrich) was used at a 50 $\mu\text{g/ml}$ concentration. Solvent for all molecules was phosphate buffered saline (PBS, Invitrogen).

Ti25Nb21Hf silanized samples were incubated overnight with a 100 μl drop of linRGD, cRGD, FN, CAS, HBII, respectively, or combinations of different proportions of CAS and HBII (30:70, 50:50 or 70:30 respectively, v/v). After incubation, samples were rinsed in PBS (x3) and blocked with 1% bovine serum albumin (BSA, Sigma-Aldrich) in PBS for 30 min. Samples were sterilized by immersion in ethanol for 30 min followed by 3 rinses in PBS.

2.6. Quartz crystal microbalance with monitoring dissipation (QCM-D)

The QCM-D was used to study the biomolecules adsorption onto silanized Ti sensors. The QCM-D (D300, Q-Sense, Sweden) measurements were performed at 37^oC by monitoring changes in frequency, Δf (Hz), and dissipation, ΔD ($\times 10^{-6}$), in real-time using Qsoft software (Q-Sense). All raw data was analyzed using QTools software (Q-Sense). Frequency and dissipation curves were fitted to a Voigt viscoelastic model to yield relevant mass, thickness, and kinetic information. The description of the Voigt model and details on its implementation using a QCM-D are reported elsewhere.^{45,46}

Monitoring of the adsorption was conducted first by completely stabilizing the baseline with PBS for 30-60 min. Then, the biomolecule of study was introduced at a concentration specified in section 2.5.2, and maintained in the sensor chamber for 60 min. Finally, the biomolecules weakly bound to the surface were rinsed with PBS for 10 min.

2.7. X-ray photoelectron spectroscopy (XPS)

XPS measurements were used to analyze the chemical composition of the samples after biomolecule immobilization. To this end, samples were silanized and coated as explained in section 2.5, and analyzed using an XPS system (SPECS Surface Nano Analysis GmbH, Berlin, Germany) equipped with a Mg anode XR50 source operating at 150 W and a Phoibos 150 MCD-9 detector. Detector pass energy was fixed at 25 eV with 0.1 eV steps to record high resolution spectra at a pressure below 7.5×10^{-9} mbar. Data was analyzed using CasaXPS software (Version 2.3.16, Casa Software Ltd., Teignmouth, UK). Binding energies were calibrated with the C1s signal located at 284.8 eV.

2.8. Cell culture

rMSCs were extracted from femurs of young Lewis rats and expanded in Advanced DMEM supplemented with 10% fetal bovine serum (FBS), 20 mM HEPES buffer solution, penicillin/streptomycin antibiotics (50 U/ml and 50 μ g/ml, respectively), 2 mM L-glutamine (all from Invitrogen) at 37 °C with 5% CO₂ and 95% relative humidity. Cells from passage 5 were used in all the experiments.

2.9. Cell adhesion

Cells (10.000 cells/sample) were seeded in each sample with serum-free medium and allowed to adhere for 4 h. Then, cells were rinsed with PBS (x3) and lysed with 300 μ l of Mammalian Protein Extraction Reagent (M-PER, Thermo Fisher, USA). The number of cells adhered was determined using the Cytotoxicity Detection Kit ^{PLUS} (LDH) (Roche, USA) following the manufacturer's instructions. The lactate dehydrogenase (LDH) activity was measured spectrophotometrically at 492 nm in a PowerWave HT microplate reader (Bio-Tek, USA). A calibration curve with decreasing number of cells was performed to express the results as cell number.

2.10. Cell spreading

Cells (25.000 cells/sample) were seeded in each sample with serum-free medium and fixed 4 h after seeding with 4% paraformaldehyde (Sigma-Aldrich) for 30 min. Fixed cells were permeabilized with 0.05% Triton X-100 in PBS at room temperature for 20 min and washed with 20 mM glycine in PBS (x3). Then samples were blocked with 1% BSA in PBS and incubated for 30 min. Next, cells were incubated with mouse anti-vinculin (1:100; Invitrogen) for 1h and rinsed with 20 mM glycine in PBS. Afterwards, samples were incubated with Alexa Fluor® 488 goat anti-mouse antibody (1:1000; Invitrogen) and TRITC-phalloidin (1:300; Invitrogen) in the dark for 1 h. After incubation, samples were washed with 20 mM glycine in PBS (x3) and nuclei were counterstained with DAPI (1:1000; Invitrogen). Finally, samples were mounted in Mowiol® 4-88 (Sigma-Aldrich) before visualizing in an E600 fluorescence microscope (Nikon Corp., Japan). Five images at 10X magnification from different areas of each sample were acquired and cell spreading was determined measuring the area of the cells using ImageJ software (National Institute of Health, USA).

2.11. Cell proliferation

Cells were seeded in serum-free medium at a density of 10.000 cells/sample. After 4 h, medium was aspirated, and cells were cultured for 7 days, 14 days and 21 days in complete medium. After each incubation period, cells were rinsed in PBS (x3) and lysed with 300 µl of M-PER. The number of cells adhered was determined using the *Cytotoxicity Detection Kit PLUS (LDH)* as described above.

2.12. Cell differentiation

Lysed cells from the proliferation assay were also used for alkaline phosphatase (ALP) detection using the SensoLyte® pNPP Alkaline Phosphatase Assay Kit (AnaSpec Inc., USA) following the manufacturer's guidelines. Reactions were incubated at 37 °C for 30 min. After

1
2
3 incubation, values of absorbance were read in a PowerWave HT microplate reader at 405 nm.
4
5 A calibration curve was prepared using purified ALP from the kit. Results were normalized
6
7 versus cell number and time of incubation.
8
9

10 **2.13. Statistical analysis**

11
12 Experiments were performed in duplicate using three replicates per each group. All data are
13
14 presented as mean values \pm standard deviations. A non-parametric Kruskal-Wallis test
15
16 followed by Mann-Whitney test with Bonferroni correction was used to determine statistical
17
18 significant (p -value <0.05) differences between the means of the different groups.
19
20
21
22
23

24 **3. RESULTS**

25 26 **3.1. Physicochemical characterization**

27 28 **3.1.1 QCM-D**

29
30
31 The thickness and surface mass density of the adlayer of immobilized biomolecule on
32
33 silanized Ti sensors determined by QCM-D analysis is shown in Table 1. Figure S1
34
35 (supplementary material) shows the changes in frequency and dissipation over time recorded
36
37 during the adsorption of the biomolecules. In all cases, the frequency rapidly decreased after
38
39 injection, reaching values of saturation after 10 and 15 min for the peptides and protein
40
41 fragments, respectively. Moreover, dissipation coefficients showed small changes during the
42
43 adsorption of peptides, while very high values were reached for HBII and to a slightly lower
44
45 extent for the CAS protein fragment. The final adsorbed mass was considerably higher for the
46
47 protein fragments (609.1 ng/cm² for CAS, 823.8 ng/cm² for HBII) than for the peptides
48
49 (220.1 ng/cm² for linRGD and 200.0 ng/cm² for cRGD).
50
51
52
53
54
55
56
57
58
59
60

3.1.2. XPS

The analysis of the chemical composition of the surfaces by XPS is summarized in Table 2. In general, the presence of the biomolecules increased the percentage of C 1s and N 1s and decreased the observed amounts of O 1s, Si 2p and Ti 2p compared to control (Ctrl) non-functionalized surfaces. These effects were more pronounced for the protein fragments (CAS and HBII) than for the peptides (linRGD and cRGD).

3.2. Cell adhesion

3.2.1. Number of cells adhered

The number of cells adhered onto each biofunctionalized surface (Fig. 1) differed depending on the immobilized molecule. Surfaces coated with linRGD, cRGD, CAS or HBII, respectively, showed a significant improvement on cell adhesion compared to FN ($p < 0.05$). There were no statistical differences on cell numbers between the peptides and the protein fragments. On the other hand, the different combinations of CAS and HB II fragments triggered different cell adhesion responses. Low concentrations of CAS (30% and 50%) stimulated an adhesion similar to that of FN, whilst a higher concentration (70%) originated a response comparable to that of linRGD, cRGD, CAS or HBII fragments alone.

3.2.2. Cell spreading

The area of cells adhered on the different biofunctionalized surfaces is shown in Fig. 2. The spreading obtained for cells in contact with linRGD and HBII respectively, was statistically lower ($p < 0.05$) than that obtained for cells in contact with FN, cRGD and CAS. When both CAS and HB II recombinant fragments were mixed, the proportion of each of the two fragments influenced cell spreading. Low percentages (30% and 50%) of CAS induced values of cell spreading close to that found on FN-coated surfaces, whereas higher values of

1
2
3 CAS (70%) led to lower projected cell areas, with values similar to those of the linear RGD
4
5 peptide and the HBII fragment alone.
6
7

8 **3.2.3. Cell morphology**

9
10 The formation of actin stress fibers (in red) was stimulated by linRGD (Fig. 3B), cRGD (Fig.
11
12 3C) and CAS (Fig. 3D), although structures resembling focal contacts were not seen in the
13
14 cells in contact with these biomolecules. Cells in contact with HBII (Fig. 3E) were not able to
15
16 generate neither actin filaments nor focal adhesions and showed ruffled borders. Noteworthy,
17
18 when both CAS and HBII were mixed with low percentages of CAS (Figs. 3F and 3G) cells
19
20 showed a cytoskeleton conformation closer to that of FN compared to the other biomolecules,
21
22 whereas the presence of CAS in high percentage (Fig. 3H) showed a cytoskeleton similar to
23
24 the CAS fragment alone.
25
26
27

28 **3.3. Cell proliferation**

29
30 The proliferation of rMSCs on the different biofunctionalized substrates after 4 h, 7 days, 14
31
32 days and 21 days in culture is shown in Fig. 4. Although cells cultured with linRGD, cRGD,
33
34 CAS or HBII, respectively, supported cell proliferation within the initial 7 days of incubation,
35
36 the number of cells on these surfaces did not reach the values obtained with FN coating,
37
38 which showed the highest values of cell growth at 21 days. Noteworthy, when CAS and HBII
39
40 recombinant fragments were mixed using less than 70% of CAS, the proliferation levels were
41
42 closer to FN samples. In contrast, for higher percentages of CAS fragment proliferation rates
43
44 were similar to short peptides or recombinant fragments separately.
45
46
47
48

49 **3.4. Cell differentiation**

50
51 Fig. 5 shows the ALP activity levels of rMSCs after 7, 14 and 21 days in culture. The first 7
52
53 days in culture, ALP levels for cells cultured on HBII and high percentage of CAS (70%)
54
55 were significantly higher compared with FN and the other molecules, which showed levels of
56
57
58
59
60

1
2
3 ALP equivalent to that of FN. After two weeks in culture, ALP from cRGD, CAS and CAS
4 (50%) was reduced whilst the other surfaces showed similar levels compared with FN and
5
6
7 between them. However, cells cultured on cRGD or CAS fragment exhibited an increase on
8
9
10 ALP levels 21 days after seeding, reaching levels similar to those of FN. Noteworthy, HBII-
11
12 coated surfaces stimulated significantly higher ALP levels than linRGD, cRGD, CAS and FN
13
14 at all time points, reaching the highest levels of ALP production after 21 days of incubation.
15
16 Combination of the HBII with a high percentage of CAS (70%) maintained this high ALP
17
18 expression. In contrast, ALP levels were significantly reduced when HBII was mixed with
19
20 lower concentrations of CAS (30% and 50%).
21
22

23 24 **4. DISCUSSION**

25
26 One approach to improve osseointegration in metallic implants is the immobilization of
27
28 bioactive molecules on their surface. Such modifications are usually achieved by
29
30 physisorption or covalent bonding. Physisorption is a non-covalent method based on Van der
31
32 Waals interactions and hydrogen bonds, which are weak and unstable interactions. In
33
34 contrast, the use of silane chemistry is a preferred and well-extended method for covalently
35
36 bounding bioactive molecules onto metallic surfaces as it provides a strong and stable
37
38 binding on the surfaces.^{22,47} In this regard, APTES has been extensively used for surface
39
40 functionalization purposes and demonstrated its suitability for the immobilization of bioactive
41
42 molecules onto Ti²² and TiNbHf alloy.⁴⁸ Moreover, in a recent study we demonstrated that
43
44 the use of APTES provides a more homogenous layer of biomolecule attachment in both Ti
45
46 and TiNbHf alloy compared to physisorption.⁴⁹ Hence, in the present work APTES was
47
48 chosen as linker molecule to immobilize the different bioactive molecules onto a recently
49
50 developed low modulus TiNbHf alloy.
51
52

53
54
55 As previously introduced, the binding of synthetic RGD peptides to Ti surfaces and TiNbHf
56
57 alloys using this silane has been recently characterized, and yielded a dense and homogenous
58
59
60

1
2
3 layer of peptide on the surfaces.⁴⁹ The number and density of molecules immobilized on
4
5 these surfaces with this method has been reported in a large number of previous studies.^{50,51}
6

7
8 However, no literature was available on the relative adsorption kinetics of the CAS and HBII
9
10 fragments on TiNbHf via APTES. QCM-D results indicated a successful attachment of both
11
12 proteins and peptides on the Ti sensors, reaching values of saturation after 10 min and 15 min
13
14 of incubation, respectively. Rinsing in PBS resulted in minor protein detachment, proving the
15
16 stability of the coatings. The amount of adsorbed protein was slightly different for each
17
18 fragment (i.e. HBII adsorbed mass was 1.3 fold higher than that of CAS). This observation
19
20 might be attributed to the distinct conformation and chemical sequence of the proteins, which
21
22 in turn results in different values of protein binding. As expected, surface mass density was
23
24 lower for peptides compared to protein fragments. The amount of adhered linRGD was
25
26 slightly higher than cRGD but differences were not statistically significant. Dissipation shift
27
28 plots indicated that during HBII protein adsorption, water was incorporated and trapped in the
29
30 layer of protein, as seen in the increasing ΔD . CAS protein layer was less viscoelastic and
31
32 both peptide adsorbed layers were more rigid compared to the HBII protein fragments layer.
33
34

35
36 XPS data confirmed QCM-D results and showed a successful biofunctionalization of the
37
38 surfaces. The observed increases in C 1s, and especially in N 1s, are common indicators of
39
40 biomolecule attachment (i.e. amide bonds).^{22,27,50,51} The reduction in the detectable signals of
41
42 Ti 2p, O 1s, and Si 2p is also consistent with the presence of biomolecules, which mask the
43
44 detection of Ti oxide and the silane layer. The binding of the protein fragments yielded the
45
46 highest variations in chemical composition (e.g. the percentage of N 1s) in comparison to the
47
48 RGD peptides. This observation is well in agreement with QCM-D values, which indicated
49
50 that the amount of proteins bound to the surfaces was higher than that of the peptides.
51
52

53
54 The interaction of cells with the different functionalized surfaces exhibited substantially
55
56 different behaviours. Both recombinant FN fragments, CAS and HBII, stimulated better cell
57
58
59
60

1
2
3 adhesion than the whole FN, and similarly to RGDs. The higher activity of a recombinant
4 FNIII₇₋₁₀ fragment compared to plasma human FN has been previously described by the
5 group of García³⁰ and associated with an enhanced affinity for integrin $\alpha 5\beta 1$. The higher
6 number of attached cells observed for RGD peptides could also be attributed to a higher
7 availability of cell adhesive motifs per area compared to native FN. Although previous
8 studies demonstrated better cell adhesion on CAS fragment than on RGDs,²⁸⁻³⁰ these
9 differences tend to disappear in saturated surface densities.²⁸ Noteworthy, HBII also
10 stimulated high cell adhesion numbers. This may be explained by the fact that cell surface
11 HSPGs may act as receptors for the HB fragment^{52,53} and that integrin receptors $\alpha 4\beta 1$ and
12 $\alpha v\beta 5$ may interact with specific sequences in this region of FN.^{52,54}

13
14 Although the number of cells was high in both FN fragments and RGDs, these cell adhesive
15 motifs were not enough to stimulate cell spreading to similar levels than the native FN. In
16 addition, the number of focal adhesions on these surfaces was lower compared to FN,
17 suggesting that their formation depends on the interaction of cell adhesion sequences with
18 other binding sites present in FN.⁵⁵ This scenario completely changed when both recombinant
19 FN fragments were mixed on the same surface. Although the number of cells increased while
20 CAS concentration was incremented, cellular spreading, cytoskeletal organization and focal
21 adhesion formation were improved with higher concentrations of HBII ($\geq 50\%$). The observed
22 critical biological role of the HBII domain is due to the presence of actin-organizing elements
23 located in the type III₁₃ repeat that stimulate the formation of focal adhesions.⁵⁵ In this study
24 we have shown that the HBII fragment alone does not support cell spreading and cytoskeletal
25 formation on the surfaces, however, in combination with small percentages of the CAS
26 domain effectively stimulates the formation of stress fibers and focal contacts, reaching cell
27 morphologies similar to FN.^{54,56,57}

28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Integrin mediated adhesion plays a major role in the regulation of cell proliferation, since it
4 stimulates crucial regulatory pathways of cell growth.⁵⁸ However, proliferation not only
5 depends on cell adhesive mechanisms but also on the interaction with soluble growth factors.
6
7
8
9
10 The growth factor receptor signalling is moreover highly regulated by integrin expression and
11 activity.^{59,60} In the present study, RGDs and the recombinant FN fragments did not induce
12 cell proliferation at levels comparable to that of full-length FN, probably due to the lack of
13 cooperation between adhesion and growth factor signalling. In contrast, the combination of
14 the CAS with high concentrations of the HBII domain ($\geq 50\%$) effectively improved
15 proliferation of rMSCs. This could be attributed to the fact that besides the cell adhesion
16 cooperative activity, HBII may also act as a growth factor binding domain. This enhancement
17 in cell proliferation was also observed in previous studies by Kim *et al.*⁵³ and Martino *et al.*,³³
18 although in their studies a molecule containing both CAS and HBII fragments fused was used
19 instead.
20

21
22 Finally, the stimulation of MSCs to differentiate into the osteoblastic lineage, also known as
23 osseointegration, is a critical step to ensure the biomaterial osseointegration. The secretion of
24 ALP has been widely used as a marker for osteoblastic differentiation. In the present study,
25 surface functionalization with a synthetic linRGD peptide was enough for stimulating rMSCs
26 differentiation despite the low integrin-specificity described for linear peptides.^{36,61}
27

28
29 In the present study, surface functionalization with a synthetic linRGD peptide was enough
30 for stimulating rMSCs differentiation. However, presentation of the RGD motif in a cyclic
31 conformation reduced the expression of ALP levels. This result should not come as a surprise
32 because cRGD shows a higher specificity than linRGD for integrins $\alpha v \beta 3$ and $\alpha v \beta 5$, but not
33 towards $\alpha 5 \beta 1$, which is well known to induce osteogenic differentiation.^{62,63} Noteworthy, the
34 presence of HBII yielded the highest levels of ALP activity probably due to the
35 aforementioned capacity to bind diverse growth factors, which may include BMP-2 and
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 BMP-7 present in the serum.⁴¹ However, the combination of HBII and CAS fragments
4
5 yielded unexpected results: whereas low percentages of HBII retained high values of ALP
6
7 expression (CAS-HBII 70:30) higher amounts reduced this activity (CAS-HBII 50:50 and
8
9 CAS-HBII 30:70) (Fig. 5).

10
11
12 The equimolar presentation of CAS and HBII (50:50) should support similar biological
13
14 profiles than full length FN. As a matter of fact, comparable cell responses were observed in
15
16 terms of cell spreading, cytoskeleton formation and proliferation (Fig. 6). In this case, the
17
18 reduced osteogenic capacity could probably respond to two factors: an insufficient quantity of
19
20 HBII motifs available for growth factor interaction or the absence of other regulatory
21
22 sequences present in FN, which may account for the osteogenic activity of the native protein.
23
24

25
26
27 It was even more intriguing that an increase in the proportion of HBII (CAS-HBII 30:70) did
28
29 not stimulate osteoblastic differentiation. We hypothesized that the reduced amount of CAS
30
31 fragment available for integrin binding would not be enough for generating stable cellular
32
33 adhesions and focal contacts, thereby engaging part of the HBII fragments in cell
34
35 adhesion/cytoskeleton organization. This would explain why even if the proportion of CAS is
36
37 reduced in the mixture CAS-HBII (30:70), the other parameters of cell behavior remain
38
39 comparable to those of FN (Fig. 6). This “co-adhesive” role for HBII would, in turn, diminish
40
41 its capacity to sequester growth factors and thus its osteogenic activity. Only when a larger
42
43 amount of HBII is present (HBII alone) both an adhesive and an osteogenic effect can be
44
45 maintained.
46
47

48
49
50 This hypothesis could also explain the opposite situation (CAS-HBII 70:30). In this context,
51
52 the high amount of CAS would be sufficient to efficiently stimulate cell adhesion and
53
54 cytoskeleton organization. This would keep a higher number of HBII fragments free for
55
56 interaction with growth factors increasing the ALP levels.
57
58
59
60

5. CONCLUSIONS

In the present study cell response to functionalised Ti25Nb21Hf alloy with two different recombinant FN fragments was studied. The results demonstrate that the mixture of CAS and HBII fragments improves cellular behaviour compared to fragments alone or synthetic RGD peptides, being a promising strategy for biomaterial implantation purposes. This response may be modulated depending on the percentage of each fragment.

When dealing with combinations of molecules that are bifunctional and/or share a similar biological function, it is important to highlight that reducing the percentage of one of the bioactive molecules in the mixture can modify the biological profile of the other one. In the present study, we observed that the reduction on the amount of cell adhesive motifs (CAS) in the mixture was accompanied with a decrease in the osteogenic activity of the HBII fragment. We hypothesized that this effect was attributed to the fact that the low percentage of CAS engaged HBII in cell adhesive processes, thus reducing its capacity to interact with growth factors and hence its osteogenic capacity.

Therefore, it should be taken into account that the equimolar presentation of two bioactive molecules may not always be an optimal approach when these molecules have partially overlapping biological roles. In these instances, the study of different percentages of each motif is recommended.

ACKNOWLEDGEMENTS

The authors would like to thank the Ministry of Economy and Competitiveness (MINECO) of the Spanish Government for financial support through MAT2012-30706 project co-funded by the EU through European Regional Development Funds and the FI fellowship of the AGAUR Agency. C. M.-M. thanks the support of the Secretary for Universities and Research of the Ministry of Economy and Knowledge of the Government of Catalonia (2011-BP-B-00042) and the People Programme (Marie Curie Actions) of the European Union's Seventh

1
2
3 Framework Programme (FP7-PEOPLE-2012-CIG, REA Grant Agreement 321985).

4
5 Technical assistance of Mrs. Montse Dominguez with XPS measurements is greatly
6
7 appreciated.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

- (1) *Titanium in Medicine: material Science, Surface Science, Engineering, Biological Responses, and Medical Applications*; Brunette, D. M., Tengvall, P., Textor, M., Thomsen, P., Eds.; Springer, Berlin, 2001.
- (2) Ridzwan, M. I. Z.; Shuib, S.; Hassan, A. Y.; Shokri, A. A.; Mohamad Ibrahim, M. N. Problem of Stress Shielding and Improvement to the Hip Implant Designs: A Review. *J. Med. Sci.* **2007**, *7* (3), 460-467.
- (3) Nobuhito, S.; Niinomi, M.; Toshikazu, A.; Takashi, S.; Tadahiko, F. Effects of Alloying Elements on Elastic Modulus of Ti-Nb-Ta-Zr System Alloy for Biomedical Applications. *Mater. Sci. Forum* **2004**, *449-452*, 1269–1272.
- (4) Hon, Y. H.; Wang, J. Y.; Pan, Y. N. Influence of Hafnium Content on Mechanical Behaviors of Ti-40Nb-xHf Alloys. *Mater. Lett.* **2004**, *58* (25), 3182–3186.
- (5) Li, Y.; Yang, C.; Zhao, H.; Qu, S.; Li, X.; Li, Y. New Developments of Ti-Based Alloys for Biomedical Applications. *Materials (Basel)* **2014**, *7* (3), 1709–1800.
- (6) Matsuno, H.; Yokoyama, A.; Watari, F.; Uo, M.; Kawasaki, T. Biocompatibility and Osteogenesis of Refractory Metal Implants, Titanium, Hafnium, Niobium, Tantalum and Rhenium. *Biomaterials* **2001**, *22* (11), 1253–1262.
- (7) Amick, D. D. Characterization of TiNbHf Alloys for Potential Medical Dental Applications. M.S. Thesis, University of Oregon, 1993.
- (8) Gonzalez, M.; Peña, J.; Manero, J. M.; Arciniegas, M.; Gil, F. J. Design and Characterization of New Ti-Nb-Hf Alloys. *J. Mater. Eng. Perform.* **2009**, *18* (5), 490-495.

- 1
2
3 (9) Herranz-Diez, C.; Gil, F.; Guillem-Marti, J.; Manero, J. Mechanical and
4
5 Physicochemical Characterization along with Biological Interactions of a New
6
7 Ti25Nb21Hf Alloy for Bone Tissue Engineering. *J. Biomater. Appl.* **2015**, *30* (2), 171–
8
9 181.
10
11
12 (10) Mas-Moruno, C.; Espanol, M.; Montufar, E. B.; Mestres, G.; Aparicio, C.; Gil, F. J.;
13
14 Ginebra, M. Bioactive Ceramic and Metallic Surfaces for Bone Engineering. In
15
16 *Biomaterials Surface Science*; Taubert, A., Mano, J. F., Rodríguez-Cabello, J. C., Eds.;
17
18 Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, **2013**; pp 337-374.
19
20
21 (11) Shekaran, A.; García, A. J. Extracellular Matrix-Mimetic Adhesive Biomaterials for
22
23 Bone Repair. *J. Biomed. Mater. Res., Part A* **2011**, *96A* (1), 261–272.
24
25
26 (12) Tejero, R.; Anitua, E.; Orive, G. Toward the Biomimetic Implant Surface:
27
28 Biopolymers on Titanium-Based Implants for Bone Regeneration. *Prog. Polym. Sci.*
29
30 **2014**, *39* (7), 1406–1447.
31
32
33 (13) Sverzut, A. T.; Crippa, G. E.; Morra, M.; de Oliveira, P. T.; Beloti, M. M.; Rosa, A. L.
34
35 Effects of Type I Collagen Coating on Titanium Osseointegration: Histomorphometric,
36
37 Cellular and Molecular Analyses. *Biomed. Mater. (Bristol, U.K.)* **2012**, *7* (3), 035007.
38
39
40 (14) Rivera-Chacon, D. M.; Alvarado-Velez, M.; Acevedo-Morantes, C. Y.; Singh, S. P.;
41
42 Gultepe, E.; Nagesha, D.; Sridhar, S.; Ramirez-Vick, J. E. Fibronectin and Vitronectin
43
44 Promote Human Fetal Osteoblast Cell Attachment and Proliferation on Nanoporous
45
46 Titanium Surfaces. *J. Biomed. Nanotechnol.* **2013**, *9* (6), 1092–1097.
47
48
49 (15) Hersel, U.; Dahmen, C.; Kessler, H. RGD Modified Polymers: Biomaterials for
50
51 Stimulated Cell Adhesion and Beyond. *Biomaterials* **2003**, *24* (24), 4385–4415.
52
53
54 (16) Williams, D. F. The Role of Short Synthetic Adhesion Peptides in Regenerative
55
56
57
58
59
60

- 1
2
3 Medicine; the Debate. *Biomaterials* **2011**, *32* (18), 4195–4197.
4
5
6 (17) Auernheimer, J.; Zukowski, D.; Dahmen, C.; Kantlehner, M.; Enderle, A.; Goodman,
7
8 S. L.; Kessler, H. Titanium Implant Materials with Improved Biocompatibility through
9
10 Coating with Phosphonate-Anchored Cyclic RGD Peptides. *Chembiochem* **2005**, *6*
11
12 (11), 2034–2040.
13
14
15 (18) Kilian, K. A.; Mrksich, M. Directing Stem Cell Fate by Controlling the Affinity and
16
17 Density of Ligand-Receptor Interactions at the Biomaterials Interface. *Angew. Chem.,*
18
19 *Int. Ed. Engl.* **2012**, *51* (20), 4891–4895.
20
21
22
23 (19) Mas-Moruno, C.; Dorfner, P. M.; Manzenrieder, F.; Neubauer, S.; Reuning, U.;
24
25 Burgkart, R.; Kessler, H. Behavior of Primary Human Osteoblasts on Trimmed and
26
27 Sandblasted Ti6Al4V Surfaces Functionalized with Integrin $\alpha\beta 3$ -Selective Cyclic
28
29 RGD Peptides. *J. Biomed. Mater. Res., Part A* **2013**, *101* (1), 87–97.
30
31
32
33 (20) Rechenmacher, F.; Neubauer, S.; Polleux, J.; Mas-Moruno, C.; De Simone, M.;
34
35 Cavalcanti-Adam, E. A.; Spatz, J. P.; Fässler, R.; Kessler, H. Functionalizing $\alpha\beta 3$ - or
36
37 $\alpha 5\beta 1$ -Selective Integrin Antagonists for Surface Coating: A Method to Discriminate
38
39 Integrin Subtypes in Vitro. *Angew. Chem., Int. Ed. Engl.* **2013**, *52* (5), 1572–1575.
40
41
42
43 (21) Rechenmacher, F.; Neubauer, S.; Mas-Moruno, C.; Dorfner, P. M.; Polleux, J.;
44
45 Guasch, J.; Conings, B.; Boyen, H.-G.; Bochen, A.; Sobahi, T. R.; Burgkart, R.; Spatz,
46
47 J. P.; Fässler, R.; Kessler, H. A Molecular Toolkit for the Functionalization of
48
49 Titanium-Based Biomaterials That Selectively Control Integrin-Mediated Cell
50
51 Adhesion. *Chemistry* **2013**, *19* (28), 9218–9223.
52
53
54
55 (22) Fraioli, R.; Rechenmacher, F.; Neubauer, S.; Manero, J. M.; Gil, J.; Kessler, H.; Mas-
56
57 Moruno, C. Mimicking Bone Extracellular Matrix: Integrin-Binding Peptidomimetics
58
59
60

- 1
2
3 Enhance Osteoblast-like Cells Adhesion, Proliferation, and Differentiation on
4 Titanium. *Colloids Surf., B* **2015**, *128*, 191–200.
- 5
6
7
8 (23) Dahmen, C.; Auernheimer, J.; Meyer, A.; Enderle, A.; Goodman, S. L.; Kessler, H.
9 Improving Implant Materials by Coating with Nonpeptidic, Highly Specific Integrin
10 Ligands. *Angew. Chem., Int. Ed. Engl.* **2004**, *43* (48), 6649–6652.
- 11
12
13 (24) Bell, B. F.; Schuler, M.; Tosatti, S.; Textor, M.; Schwartz, Z.; Boyan, B. D. Osteoblast
14 Response to Titanium Surfaces Functionalized with Extracellular Matrix Peptide
15 Biomimetics. *Clin. Oral Implants Res.* **2011**, *22* (8), 865–872.
- 16
17
18 (25) Yin, W.-N.; Cao, F.-Y.; Han, K.; Zeng, X.; Zhuo, R.-X.; Zhang, X.-Z. The Synergistic
19 Effect of a BMP-7 Derived Peptide and Cyclic RGD in Regulating Differentiation
20 Behaviours of Mesenchymal Stem Cells. *J. Mater. Chem. B* **2014**, *2* (47), 8434–8440.
- 21
22
23 (26) Lin, W.; Junjian, C.; Chengzhi, C.; Lin, S.; Sa, L.; Li, R.; Yingjun, W. Multi-
24 Biofunctionalization of a Titanium Surface with a Mixture of Peptides to Achieve
25 Excellent Antimicrobial Activity and Biocompatibility. *J. Mater. Chem. B* **2015**, *3* (1),
26 30–33.
- 27
28
29 (27) Mas-Moruno, C.; Fraioli, R.; Albericio, F.; Manero, J. M.; Gil, F. J. Novel Peptide-
30 Based Platform for the Dual Presentation of Biologically Active Peptide Motifs on
31 Biomaterials. *ACS Appl. Mater. Interfaces* **2014**, *6* (9), 6525–6536.
- 32
33
34 (28) Petrie, T. A.; Capadona, J. R.; Reyes, C. D.; García, A. J. Integrin Specificity and
35 Enhanced Cellular Activities Associated with Surfaces Presenting a Recombinant
36 Fibronectin Fragment Compared to RGD Supports. *Biomaterials* **2006**, *27* (31), 5459–
37 5470.
- 38
39
40 (29) Petrie, T. A.; Raynor, J. E.; Reyes, C. D.; Burns, K. L.; Collard, D. M.; García, A. J.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 The Effect of Integrin-Specific Bioactive Coatings on Tissue Healing and Implant
4 Osseointegration. *Biomaterials* **2008**, *29* (19), 2849–2857.
5
6
7
8 (30) Petrie, T. A.; Reyes, C. D.; Burns, K. L.; García, A. J. Simple Application of
9 Fibronectin-Mimetic Coating Enhances Osseointegration of Titanium Implants. *J.*
10 *Cell. Mol. Med.* **2009**, *13* (8b), 2602–2612.
11
12
13
14
15 (31) Martino, M. M.; Mochizuki, M.; Rothenfluh, D. A.; Rempel, S. A.; Hubbell, J. A.;
16 Barker, T. H. Controlling Integrin Specificity and Stem Cell Differentiation in 2D and
17 3D Environments through Regulation of Fibronectin Domain Stability. *Biomaterials*
18 **2009**, *30* (6), 1089–1097.
19
20
21
22
23
24
25 (32) Traub, S.; Morgner, J.; Martino, M. M.; Höning, S.; Swartz, M. A.; Wickström, S. A.;
26 Hubbell, J. A.; Eming, S. A. The Promotion of Endothelial Cell Attachment and
27 Spreading Using FNIII10 Fused to VEGF-A165. *Biomaterials* **2013**, *34* (24), 5958–
28 5968.
29
30
31
32
33
34
35 (33) Martino, M. M.; Tortelli, F.; Mochizuki, M.; Traub, S.; Ben-David, D.; Kuhn, G. A.;
36 Müller, R.; Livne, E.; Eming, S. A.; Hubbell, J. A. Engineering the Growth Factor
37 Microenvironment with Fibronectin Domains to Promote Wound and Bone Tissue
38 Healing. *Sci. Transl. Med.* **2011**, *3* (100), 100ra89.
39
40
41
42
43
44
45 (34) Martino, M. M.; Briquez, P. S.; Güç, E.; Tortelli, F.; Kilarski, W. W.; Metzger, S.;
46 Rice, J. J.; Kuhn, G. A.; Müller, R.; Swartz, M. A.; Hubbell, J. A. Growth Factors
47 Engineered for Super-Affinity to the Extracellular Matrix Enhance Tissue Healing.
48 *Science* **2014**, *343* (6173), 885–888.
49
50
51
52
53
54
55 (35) Pankov, R.; Yamada, K. M. Fibronectin at a Glance. *J. Cell Sci.* **2002**, *115* (20), 3861–
56 3863.
57
58
59
60

- 1
2
3 (36) Aota, S.; Nomizy, M.; Yamada, J. M. The Short Amino Acid Sequence Pro-His-Ser-
4 Arg-Asn in Human Fibronectin Enhances Cell-Adhesive Function. *J. Biol. Chem.*
5 **1994**, *269* (40), 24756–24761.
6
7
8
9
10 (37) Ku, Y.; Chung, C.-P.; Jang, J.-H. The Effect of the Surface Modification of Titanium
11 Using a Recombinant Fragment of Fibronectin and Vitronectin on Cell Behavior.
12 *Biomaterials* **2005**, *26* (25), 5153–5157.
13
14
15
16
17 (38) Agarwal, R.; González-García, C.; Torstrick, B.; Guldberg, R. E.; Salmerón-Sánchez,
18 M.; García, A. J. Simple Coating with Fibronectin Fragment Enhances Stainless Steel
19 Screw Osseointegration in Healthy and Osteoporotic Rats. *Biomaterials* **2015**, *63*,
20 137–145.
21
22
23
24
25
26
27 (39) Sarrazin, S.; Lamanna, W. C.; Esko, J. D. Heparan Sulfate Proteoglycans. *Cold Spring*
28 *Harbor Perspect. Biol.* **2011**, *3* (7), a004952.
29
30
31
32 (40) Elfenbein, A.; Simons, M. Syndecan-4 Signaling at a Glance. *J. Cell Sci.* **2013**, *126* (Pt
33 17), 3799–3804.
34
35
36
37 (41) Martino, M. M.; Hubbell, J. A. The 12th-14th Type III Repeats of Fibronectin
38 Function as a Highly Promiscuous Growth Factor-Binding Domain. *FASEB J.* **2010**,
39 *24* (12), 4711–4721.
40
41
42
43
44 (42) Albericio, F. Developments in Peptide and Amide Synthesis. *Curr. Opin. Chem. Biol.*
45 **2004**, *8* (3), 211–221.
46
47
48
49 (43) Kantlehner, M.; Schaffner, P.; Finsinger, D.; Meyer, J.; Jonczyk, A.; Diefenbach, B.;
50 Nies, B.; Hölzemann, G.; Goodman, S. L.; Kessler, H. Surface Coating with Cyclic
51 RGD Peptides Stimulates Osteoblast Adhesion and Proliferation as Well as Bone
52 Formation. *Chembiochem* **2000**, *1* (2), 107–114.
53
54
55
56
57
58
59
60

- 1
2
3 (44) Haubner, R.; Gratiás, R.; Diefenbach, B.; Goodman, S. L.; Jonczyk, A.; Kessler, H.
4
5 Structural and Functional Aspects of RGD-Containing Cyclic Pentapeptides as Highly
6
7 Potent and Selective Integrin $\alpha V \beta 3$ Antagonists. *J. Am. Chem. Soc.* **1996**, *118* (32),
8
9 7461–7472.
10
11
12 (45) Höök, F.; Kasemo, B.; Nylander, T.; Fant, C.; Sott, H. Variations in Coupled Water,
13
14 Viscoelastic Properties, and Film Thickness of a Mefp-1 Protein Film during
15
16 Adsorption and Cross-Linking: A Quartz Crystal Microbalance with Dissipation
17
18 Monitoring, Ellipsometry, and Surface Plasmon Resonance Study. *Anal. Chem.* **2001**,
19
20 *73*, 5796-5804.
21
22
23
24 (46) Pegueroles, M.; Tonda-Turo, C.; Planell, J. A.; Gil, F. J.; Aparicio, C. Adsorption of
25
26 Fibronectin, Fibrinogen, and Albumin on TiO₂: Time-Resolved Kinetics, Structural
27
28 Changes, and Competition Study. *Biointerphases* **2012**, *7* (1), 1-13.
29
30
31
32 (47) Chen, X.; Sevilla, P.; Aparicio, C. Surface Biofunctionalization by Covalent Co-
33
34 Immobilization of Oligopeptides. *Colloids Surf., B* **2013**, *107*, 189–197.
35
36
37
38 (48) Paredes, V.; Salvagni, E.; Rodríguez-Castellon, E.; Gil, F. J.; Manero, J. M. Study on
39
40 the Use of 3-Aminopropyltriethoxysilane and 3-Chloropropyltriethoxysilane to
41
42 Surface Biochemical Modification of a Novel Low Elastic Modulus Ti-Nb-Hf Alloy.
43
44 *J. Biomed. Mater. Res., Part B* **2014**, *103* (3), 495-502.
45
46
47 (49) Herranz-Diez, C.; Li, Q.; Lamprecht, C.; Mas-Moruno, C.; Neubauer, S.; Kessler, H.;
48
49 Manero, J. M.; Guillem-Martí, J.; Selhuber-Unkel, C. Bioactive Compounds
50
51 Immobilized on Ti and TiNbHf: AFM-Based Investigations of Biofunctionalization
52
53 Efficiency and Cell Adhesion. *Colloids Surf., B* **2015**, *136*, 704–711.
54
55
56
57 (50) Xiao, S.-J.; Textor, M.; Spencer, N. D.; Sigrist, H. Covalent Attachment of Cell-
58
59
60

- 1
2
3 Adhesive, (Arg-Gly-Asp)-Containing Peptides to Titanium Surfaces. *Am. Chem. Soc.*
4
5 **1998**, *14* (19), 5507–5516.
6
7
- 8 (51) Xiao, S. J.; Textor, M.; Spencer, N. D.; Wieland, M.; Keller, B.; Sigrist, H.
9
10 Immobilization of the Cell-Adhesive Peptide Arg–Gly–Asp–Cys (RGDC) on Titanium
11
12 Surfaces by Covalent Chemical Attachment. *J. Mater. Sci.: Mater. Med.* **1997**, *8* (12),
13
14 867–872.
15
16
- 17 (52) Woods, A.; Couchman, J. R.; Johansson, S.; Höök, M. Adhesion and Cytoskeletal
18
19 Organisation of Fibroblasts in Response to Fibronectin Fragments. *EMBO J.* **1986**, *5*
20
21 (4), 665–670.
22
23
- 24 (53) Kim, J.-H.; Park, S.-O.; Jang, H.-J.; Jang, J.-H. Importance of the Heparin-Binding
25
26 Domain of Fibronectin for Enhancing Cell Adhesion Activity of the Recombinant
27
28 Fibronectin. *Biotechnol. Lett.* **2006**, *28* (17), 1409–1413.
29
30
- 31 (54) Dalton, B. A.; McFarland, C. D.; Underwood, P. A.; Steele, J. G. Role of the Heparin
32
33 Binding Domain of Fibronectin in Attachment and Spreading of Human Bone-Derived
34
35 Cells. *J. Cell Sci.* **1995**, *108* (5), 2083–2092.
36
37
- 38 (55) Bloom, L.; Ingham, K. C.; Hynes, R. O. Fibronectin Regulates Assembly of Actin
39
40 Filaments and Focal Contacts in Cultured Cells via the Heparin-Binding Site in Repeat
41
42 III13. *Mol. Biol. Cell* **1999**, *10* (5), 1521–1536.
43
44
- 45 (56) Yoneda, J.; Saiki, I.; Igarashi, Y.; Kobayashi, H.; Fujii, H.; Ishizaki, Y.; Kimizuka, F.;
46
47 Kato, I.; Azuma, I. Role of the Heparin-Binding Domain of Chimeric Peptides Derived
48
49 from Fibronectin in Cell Spreading and Motility. *Exp. Cell Res.* **1995**, *217* (1), 169–
50
51 179.
52
53
- 54 (57) Kang, W.; Park, S.; Jang, J.-H. Kinetic and Functional Analysis of the Heparin-
55
56
57
58
59
60

- 1
2
3 Binding Domain of Fibronectin. *Biotechnol. Lett.* **2008**, *30* (1), 55–59.
4
5
6 (58) Schwartz, M. A.; Assoian, R. K. Integrins and Cell Proliferation: Regulation of Cyclin-
7
8 Dependent Kinases via Cytoplasmic Signaling Pathways. *J. Cell Sci.* **2001**, *114* (14),
9
10 2553–2560.
11
12
13 (59) Baron, V.; Schwartz, M. Cell Adhesion Regulates Ubiquitin-Mediated Degradation of
14
15 the Platelet-Derived Growth Factor Receptor Beta. *J. Biol. Chem.* **2000**, *275* (50),
16
17 39318–39323.
18
19
20
21 (60) Moro, L. Integrins Induce Activation of EGF Receptor: Role in MAP Kinase Induction
22
23 and Adhesion-Dependent Cell Survival. *EMBO J.* **1998**, *17* (22), 6622–6632.
24
25
26 (61) García, A. J.; Reyes, C. D. Bio-Adhesive Surfaces to Promote Osteoblast
27
28 Differentiation and Bone Formation. *J. Dent. Res.* **2005**, *84*, 407.
29
30
31 (62) Hughes, D. E.; Salter, D. M.; Dedhar, S.; Simpson, R. Integrin Expression in Human
32
33 Bone. *J. Bone Miner. Res.* **1993**, *8* (5), 527–533.
34
35
36 (63) Grzesik, W. J.; Robey, P. G. Bone Matrix RGD Glycoproteins: Immunolocalization
37
38 and Interaction with Human Primary Osteoblastic Bone Cells in Vitro. *J. Bone Miner.*
39
40 *Res.* **1994**, *9* (4), 487–496.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

TABLES

Table 1. QCM-D study of the thickness and surface mass density of the bound biomolecules to silanized Ti sensors calculated using the Voigt model.

Biomolecules	Thickness (nm)	Surface mass density (ng/cm ²)
CAS	5,54 (±0,09)	609,14 (±10,19)
HBII	7,49 (±0,13)	823,80 (±14,00)
linRGD	2,00 (±0,17)	220,12 (±9,17)
cRGD	1,82 (±0,14)	200,01 (±14,98)

Table 2. Surface chemical composition (expressed as atomic percentages) of the biofunctionalized samples by XPS.

	C 1s	N 1s	O 1s	Si 2p	Ti 2p
Ctrl	22,96 (± 1.87)	0,76 (± 0.19)	56,25 (± 1.45)	0,49 (± 0.08)	19,57 (± 0.15)
CAS	47,63 (± 0.13)	10,57 (± 0.25)	31,93 (± 0.04)	3,01 (± 0.06)	6,87 (± 0.23)
HBII	46,45 (± 1.48)	10,26 (± 0.53)	32,85 (± 1.22)	3,66 (± 0.08)	6,78 (± 0.72)
linRGD	32,16 (± 0.42)	4,82 (± 0.03)	46,31 (± 0.33)	4,82 (± 0.33)	11,91 (± 0.28)
cRGD	34,77 (± 1.07)	5,33 (± 0.05)	43,55 (± 0.76)	5,53 (± 0.04)	10,83 (± 0.30)

FIGURE CAPTIONS

Fig. 1. Adhesion of rMSCs onto Ti25Nb21Hf alloy biofunctionalized with the different biomolecules after 4 h of culture. Letter “a” indicates study groups with no statistical differences with FN. Letter “b” indicates study groups with statistically significant differences compared to FN.

Fig. 2. Spreading of rMSCs onto Ti25Nb21Hf alloy biofunctionalized with the different biomolecules after 4 h of culture. Letter “a” indicates study groups with no statistical differences with FN. Letter “b” indicates study groups with statistically significant differences compared to FN.


Fig. 3. Representative high magnification images (60x) of rMSCs spreading and morphology after 4h in culture with FN (A), linRGD (B), cRGD (C), CAS (D), HB II (E), CAS-HBII 30:70 (F), CAS-HBII 50:50 (G) and CAS-HBII (H) biofunctionalized surfaces. Scale bar 20 μm .

Fig. 4. Proliferation of rMSCs onto Ti25Nb21Hf alloy biofunctionalized with the different biomolecules. At each time, “a”, “c”, “g” and “k” indicates no statistical differences compared to FN while distinct letters denote statistical differences to FN and between conditions.

Fig. 5. ALP activity of rMSCs onto Ti25Nb21Hf alloy biofunctionalized with the different biomolecules. At each time, “a”, “c” and “e” indicates no statistical differences compared to FN while distinct letters denote statistical differences to FN and between conditions.

Fig. 6. Summary of cell responses to functionalized surfaces with FN, different mixtures of CAS and HBII fragments (30:70, 50:50 and 70:30) and CAS and HBII fragments alone. Biomolecules with similar responses were grouped by colors for better interpretation of results.

TABLE OF CONTENTS (TOC)






Fig. 1. Adhesion of rMSCs onto Ti25Nb21Hf alloy biofunctionalized with the different biomolecules after 4 h of culture. Letter "a" indicates study groups with no statistical differences with FN. Letter "b" indicates study groups with statistically significant differences compared to FN.

68x55mm (300 x 300 DPI)




Fig. 2. Spreading of rMSCs onto Ti25Nb21Hf alloy biofunctionalized with the different biomolecules after 4 h of culture. Letter "a" indicates study groups with no statistical differences with FN. Letter "b" indicates study groups with statistically significant differences compared to FN.
73x63mm (300 x 300 DPI)




Fig. 3. Representative high magnification images (60x) of rMSCs spreading and morphology after 4h in culture with FN (A), linRGD (B), cRGD (C), CAS (D), HB II (E), CAS-HBII 30:70 (F), CAS-HBII 50:50 (G) and CAS-HBII (H) biofunctionalized surfaces. Scale bar 20 μ m.
42x65mm (300 x 300 DPI)




Fig. 4. Proliferation of rMSCs onto Ti25Nb21Hf alloy biofunctionalized with the different biomolecules. At each time, "a", "c", "g" and "k" indicates no statistical differences compared to FN while distinct letters denote statistical differences to FN and between conditions.
58x40mm (300 x 300 DPI)




Fig. 5. ALP activity of rMSCs onto Ti25Nb21Hf alloy biofunctionalized with the different biomolecules. At each time, "a", "c" and "e" indicates no statistical differences compared to FN while distinct letters denote statistical differences to FN and between conditions.
59x42mm (300 x 300 DPI)




Fig. 6. Summary of cell responses to functionalized surfaces with FN, different mixtures of CAS and HBII fragments (30:70, 50:50 and 70:30) and CAS and HBII fragments alone. Biomolecules with similar responses were grouped by colors for better interpretation of results.
84x40mm (300 x 300 DPI)




Table of Contents (TOC)
112x44mm (300 x 300 DPI)